3. OBJECTIVE OF PRESENT INVESTIGATION

- Palonosetron antiemetic drug required to be fast acting & thus must have high bioavailability in prior publications & formulation the high bioavailability allegedly, has been achieved by providing drug as a liquid preparation ex: as i.v Injection or other liquid preparation as encapsulated liquids.

- In view of stability problems associated with liquid formulation containing Palonosetron & its salts there is need to provide stable formulation preferable without the use of one or more excipients or chemical agents to provide oxygen mediated degradation of Palonosetron in the dosage form. Preferable it would be desirable to form a dosage form comprising of Palonosetron or a pharmaceutically acceptable salt thereof in solid phase.

- On this context it is better to have orodispersible tablets rather than conventional tablets as in case of orodisperible tablets there is less utilization of water which is a potential source for oxidation further degradation of Palonosetron, compared to conventional tablets & more potential advantages than conventional tablets on several fronts it is decided to prepare formulation of orodisperible tablets.